Brenneisen


	University of Bern Department of Clinical Research	Murtenstrasse 35 CH-3010 Bern, Switzerland

Laboratory of Phytopharmacology, Bioanalytics & Pharmacokinetics

Group Prof. R. Brenneisen

Address

Prof. Dr. Rudolf Brenneisen
Department of Clinical Research, University of Bern,
Murtenstrasse 35, CH-3010 Bern, Switzerland

Map

Phone / Fax

++41-(0)31-63 287 14 / ++41-(0)31-63 232 97

E-Mail

rudolf.brenneisen@dkf.unibe.ch

Group Members

Rudolf Brenneisen, PhD, Professor, Head

CV:

1975 Federal Diploma (M.S.) for Pharmaceutical Sciences, University of Bern (UNIBE); 1979 Ph.D. for Phytochemistry & Pharmacognosy, UB (Prof. E. Steinegger); Assistant Professor for Phytochemistry & Pharmacognosy (Research & Teaching), Institute of Pharmacy, UNIBE; 1981 Head of the Dept. of Phytochemistry & Pharmacognosy, Institute of Pharmacy, UNIBE; 1987 Visiting Research Scientist at the University of Mississippi, School of Pharmacy, Research Institute of Pharmaceutical Sciences (Prof. M.A. ElSohly);1988 Habilitation at the Faculty of Medicine, UNIBE, for "Pharmaceutical Phytochemistry & Pharmacognosy"; Privatdozent (PD) for "Pharmaceutical Phytochemistry & Pharmacognosy"; 1989- Consultant/ Expert, United Nations International Drug Control Programme (UNDCP); 1990-91 Vice-Director, Institute of Pharmacy, UNIBE; 1993 Associated Professor, UNIBE; 1993- Consultant/Expert, Federal Office of Public Health, Div. of Pharmaceuticals & Narcotics; 1993- Member of the Swiss Guideline Committee for Drug Abuse Testing (AGSA); 1994-96 Head of the Analytical Toxicology Unit, Institute of Pharmacy, UNIBE; 1997- Head of the „Laboratory for Pharmaceutical Analysis, Pharmacokinetics and Toxicology“, Dept. of Clinical Research (DKF), UNIBE; 1997-2007 Member of the scientific advisory board of the „International Association of Cannabis as Medicine (IACM)“; 2006- Member of the scientific advisory board of "Cannabinoids" (IACM); 2007- Member of the advisory committee of the "Journal of Phytopharmacotherapy and Natural Products".(JPNP); 2009- Member of the executive board of directors of the „International Association of Cannabis as Medicine (IACM); 2007- Member of the Scientific Council of the Swiss Society of Pharmaceutical Sciences, SGPhW (SSPhS); 2008- President Scientific Advisory Board of The Swiss Academy of Pharmaceutical Sciences, SAPhS; Advisory Board Swiss ALS Association (ALS); President Swiss Committee for Drugs of Abuse Testing SCDAT (SCDAT).

Memberships:

Society for Medicinal Plant Research (GA); American Academy of Forensic Sciences (AAFS), Section of Toxicology (Fellow); The International Association of Forensic Toxicologists (TIAFT); The Society of Forensic Toxicologists (SOFT); German Association of Toxicology and Forensic Chemistry (GTFCh); Society of Swiss Pharmacists; Society of Bernese Pharmacists (honorary member); Swiss Society for Pharmaceutical Sciences (SGPhW); European Workplace Drug Testing Working Group/Soc. (EWDTG/EWDTS); The International Cannabinoid Research Society (ICRS).

Main research interests:
see below.

Christian Lanz, Pharmacist, PhD, Lab Supervisor

2010 to present: Research fellow in analytical chemistry (HPLC, gas chromatography-mass spectrometry) at the Department of Clinical Research, University of Bern (group Prof. R. Brenneisen); 2006-2010: Research fellow in analytical chemistry (gas chromatography mass spectrometry), metabolomics and chemometrics (multivariate data analysis) at the Institute of Clinical Pharmacology and Visceral Research, University of Bern (Prof. Jeff Idle); 2005-2006: Deputy laboratory head of the routine analytical laboratory of the Institute of Clinical Pharmacology, University of Bern; 2004-2005: Postdoc in analytical chemistry (liquid chromatography) at the Institute of Clinical Pharmacology, University of Bern (Prof. T. Cerny, St. Gallen); 2004: PhD (Dr. phil.) in analytical chemistry, graduated from the University of Basel, "Determination of carbohydrate-deficient transferrin in human serum by capillary zone electrophoresis"; 2001-2004: PhD student in analytical chemistry (capillary electrophoresis) at the Institute of Clinical Pharmacology, University of Bern and Basel (Prof. W. Thormann); 1999: Federal diploma in Pharmacy (eidg. dipl. Apotheker), University of Basel; 1993-1999 Study of Pharmaceutical Sciences, University of Bern, ETH Zurich and University of Basel.

Johan Mattson, Chemist, PhD

2006-2010: PhD student at University of Neuchatel under the supervision of Dr. Bruno Therrien and Prof. Georg Süss-Fink, Thesis title “molecular arene ruthenium cages; new drug delivery vectors to cancer cells”. 2006: Mälardalens University, Research Project, Research under the supervision of Dr. Sarah Angus-Dunne on ligand synthesis, complex synthesis and crystallization. 2004: Master Thesis at University of Queensland,

Australia,

under Prof. Paul V. Bernhardt on ligand synthesis and complex synthesis 2000-2005: Mälardalen University,

Sweden.

Chemical Engineering program with focus on drug design.

Karin Fürer, Pharmacist, PhD student

2010-present : PhD thesis work «Clinical effects, analytics, and pharmacology of Bryophyllum», University Hospital of Zurich, University of Bern and Basel; 2008-2010 Working in a public pharmacy; 2008: Master of Science in Pharmacy, University of Basel; 2007: Master thesis «Non-functional PI3Kd lead to impaired lymphocyte proliferation and cytokine secretion during alloreactivity.“, performed at Novartis Basel.

Raoul Yankam, Chemist

2010, Master's Degree of Chemistry, University of Geneva; 2008, Bachelor's Degree of Engineering in Chemical and Biochemical Technology, Moscow D.I. Mendeleev University of Chemical Technology, Russia.

Infrastructure and instrumentation:

Ongoing projects (status March 2011):

In vitro and in vivo validation of cannabinoid aerosols for pulmonal application.
Psycho- and neuropharmacology of intravenous THC.
Pharmacokinetics of THC in ALS patients.
Function of phyto- and endocannabinoids in liver diseases.
Bioanalytics of endocannabinoids.
Phytochemistry, pharmacology and clinics of Bryophyllum species.
Determination of drugs and drugs of abuse loads in wastewater of Swiss sewage treatment plants to estimate drug consumption.
LSD as adjunct in psychotherapy.
(Psycho)pharmacology and pharmacokinetics of MDMA.
(Psycho)pharmacology and pharmacokinetics of diacetylmorphine.

Selected references 2010-2011:

Simoes-Wüst AP, Graos M, Duarte CB, Brenneisen R, Hamburger M, Mennet M, Ramos F MH, Schnelle M, Wächter R, Worel AM, von Mandach U.
Juice of Bryophyllum pinnatum (Lam.) inhibits oxytocin-induced increase of the intracellular clacium concentration in human myometrial cells.
Phytomedicine 2010; 17: 980-86.

Mareck U, Haenelt N, Geyer H, Guddat S, Kamber M, Brenneisen R, Thevis M, Schänzer W.
Temporal indication of cannabis use by means of THC glucuronide determination.
Drug Test. Analysis 2009; 1: 505-510.

Brenneisen R, Meyer P, Chtioui H, Saugy M, Kamber M.
Plasma and urine profiles of delta-9-tetrahydrocannabinol (THC) and its metabolites 11-hydroxy-THC and 11-nor-9-carboxy-THC
after cannabis smoking by healthy volunteers to estimate recent consumption of athletes.
Anal. Bioanal. Chem. 2010; 396: 2493-2502.

Berset J-D, Brenneisen R, Mathieu C.
Analysis of llicit and illicit drugs in waste, surface and lake water samples using large volume direct injection
high performance liquid chromatography – Electrospray tandem mass spectrometry (HPLC-MS/MS).
Chemosphere 2010; 81: 859-66.

Mathieu C, Rieckermann J, Berset J-D, Schürch S, Brenneisen R.
Assessment of total uncertainty in cocaine and benzoylecgonine wastewater load measurements.
Water Research 2011; 45: 6650-60.

Hysek CM, Simmler LD, Ineichen M, Grouzmann E, Hoener MC, Brenneisen R, Huwyler J, Liechti ME.
The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA (“Ecstasy”) in humans.
Clin Pharm Ther (advance online pub, doi 10.1038/clpt.2011.78)

Morrison PD, Nottage J, Stone JW, Bhattacharyya S, Tunstall N, Brenneisen R, Holt D, Wilson D, Sumich A, McGuire P, Murray RM, Kapur S, Ffytche D.
Disruption of frontal theta coherence by Δ9- tetrahydrocannabinol is associated with positive psychotic symptoms.
Neuropsychopharmacology 2011; 36 : 827-36 (epub ahead doi:10.1038/npp.2010.222).

Barkus E, Morrison PD, Vuletic D, Dickson J, Ell PJ, Pilowsky LS, Brenneisen R., Holt DW, Powell J, Kapur S, Murray RM.
Does intravenous delta-9-tetrahydrocannabinol increase dopamine release? A SPET study.
J Psychopharmacol 2010 (advance online pub,doi 10.1177/0269881110382465).

Stone JM, Morrison PD, Brugger S, Nottage J, Bhattacharyya S, Sumich A, Wilson D, Tunstall N, Feilding A, Brenneisen R, McGuire P, Murray RM, Ffytche DH.
Communication breakdown: delta-9-tetrahydrocannabinol effects on pre-speech neural coherence.
Molecular Psychiatry (advance online pub, doi: 10.1038/mp.2011.141).

Wächter R, Brenneisen R, Hamburger M, Mennet M, Schnelle M, Worel AM, Simões-Wüst AP, von Mandach U.
Leaf press juice from Bryophyllum pinnatum (Kalanchoe pinnata L.) induces myometrial relaxation.
Phytomedicine 2011 (epub ahead, doi.org/10.1016/j.phymed.20111.06.032).

Patsenker E, Stoll M, Millonig G, Agaimy A, Wissniowski T, Schneider V, Mueller S, Brenneisen R, Seitz H, Ocker M, Stickel F.
Cannabinoid receptor type I modulates alcohol-induced liver fibrosis.
Molecular Medicine (in press).

Conference presentations:

Cultiva Wien / CAM Congress, 30.-31. Okt. 2010:

Cannabis in der Medizin - Update

University of Innsbruck, Institute of Pharmacy, 8. Nov. 2010:

Cannabis in der Medizin - Ein Update

10th Int. Conference of the Society of Neuroscientists in Africa (SONA), 9. Febr. 2011, Addis Ababa:

CNS-stimulating and somatic effects of Khat

Swiss Society and Academy of Pharmaceutical Sciences (SSPhS, SAPhS)

SGPhW